CASEY MCGRATH: Open Payments
NPI 1821632324 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,125 in 108 payments from 20 companies in 2025. Trend: 2023 $1,836 · 2024 $1,920 · 2025 $2,125
Food & beverage: $2,125
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $375 |
| GlaxoSmithKline, LLC. | 12 | $296 |
| Novo Nordisk Inc | 12 | $251 |
| Lilly USA, LLC | 8 | $174 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $150 |
| AstraZeneca Pharmaceuticals LP | 8 | $141 |
| PFIZER INC. | 12 | $137 |
| Astellas Pharma US Inc | 3 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| Kowa Pharmaceuticals America, Inc. | 4 | $73 |
Products named: TRELEGY ELLIPTA, VRAYLAR, MOUNJARO, Ozempic, REXULTI, CAPLYTA, Veozah, QULIPTA.
Industry payments across PA — which companies pay providers there.
